Home News

First quarter 2019 results presentation

Operating income, growth figures, profitability and how our products have behaved

Wed, 08/05/2019 - 12:15 0 min
Download related document
No votes yet
 
Related
ROVI reports operating revenue growth of 26% and EBITDA growth of 106%
ROVI reports operating revenue growth of 26% and EBITDA growth of 106%
Operating revenue increased by 26% to 381.3 million euros in 2019, mainly driven by the strength of the specialty pharmaceutical...
6 min
26/02/2020
ROVI announces the commencement of the assessment process to obtain marketing authorisation for Doria® in the European Union
ROVI announces the commencement of the assessment process to obtain marketing...
ROVI filed its application for marketing authorisation for Doria® with the European health authorities, the European Medicines Agency (EMA...
2 min
31/01/2020
2019 Investor Day presentation
0 min
25/11/2019